At the conclusion of the Facilitated Dialogue on Closed Generics, the participants met and discussed the Facilitated Dialogue process, offering their feedback on various aspects of this new initiative. The participants' feedback is captured in the document below.
*Please note that these inputs represent the individual opinions of the Facilitated Dialogue participants, and do not represent the views of their appointing SO/ACs.
